HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hemp Supplement Sales Continue In US Without FDA Acknowledgement As Lawful Products

Executive Summary

Decision, explained by Principal Deputy Commissioner Woodcock, turns page on FDA’s 2019 announcement, after hemp was de-scheduled in 2018 farm bill, it would consider rulemaking for lawful use of hemp in supplements.

You may also be interested in...



Industry Groups Put It In Writing: House Hearing Needed On FDA Hemp 'Regulation, Or Lack Thereof'

Hemp, supplement industry groups say Energy and Commerce hearing is needed on FDA’s “regulation, or lack thereof, of the rapidly growing hemp market.”

Congress Hearing Chorus Of Trade Groups’ Concerns About FDA’s Hemp Regulatory Conundrum

AHPA, CHPA and UNPA say “current statutory definitions already apply to hemp and its extracts and naturally occurring constituents” and “there is no need for a new regulatory pathway to include these ingredients in dietary supplements.” CRN and USHR also assert FDA currently has regulatory tools to allow hemp ingredients’ use in food and supplements.

US Hemp Supplement Market Could Go Up In Smoke, Cast Cloud On Cannabis Without Regulation

Market's direction depends on different influences, according to witnesses testifying at recent House hearing looking at FDA’s position on using hemp ingredients in food and dietary supplements. Rising costs and plummeting prices hit marketers as acreage for hemp and amount harvested shrink.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel